Chemed Co. (NYSE:CHE) Stock Position Increased by Signal Advisors Wealth LLC

Signal Advisors Wealth LLC raised its position in shares of Chemed Co. (NYSE:CHE) by 60.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,995 shares of the company’s stock after purchasing an additional 1,886 shares during the period. Signal Advisors Wealth LLC’s holdings in Chemed were worth $2,647,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. EP Wealth Advisors LLC lifted its position in Chemed by 1.9% in the third quarter. EP Wealth Advisors LLC now owns 1,354 shares of the company’s stock worth $814,000 after purchasing an additional 25 shares during the period. Ballentine Partners LLC raised its stake in shares of Chemed by 4.1% in the 3rd quarter. Ballentine Partners LLC now owns 655 shares of the company’s stock worth $394,000 after buying an additional 26 shares in the last quarter. Creative Planning lifted its holdings in shares of Chemed by 2.8% in the second quarter. Creative Planning now owns 1,228 shares of the company’s stock valued at $667,000 after buying an additional 34 shares during the period. First Heartland Consultants Inc. grew its holdings in Chemed by 7.2% during the third quarter. First Heartland Consultants Inc. now owns 508 shares of the company’s stock worth $305,000 after acquiring an additional 34 shares during the period. Finally, First Trust Direct Indexing L.P. raised its position in Chemed by 4.5% in the third quarter. First Trust Direct Indexing L.P. now owns 887 shares of the company’s stock worth $533,000 after acquiring an additional 38 shares in the last quarter. Institutional investors own 95.85% of the company’s stock.

Chemed Stock Up 1.7 %

Shares of Chemed stock opened at $530.55 on Tuesday. Chemed Co. has a 12-month low of $512.12 and a 12-month high of $654.62. The firm has a market capitalization of $7.98 billion, a PE ratio of 26.81, a price-to-earnings-growth ratio of 2.32 and a beta of 0.47. The stock’s fifty day moving average is $545.44 and its 200-day moving average is $562.63.

Chemed (NYSE:CHE) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $5.64 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.76 by ($0.12). Chemed had a return on equity of 27.86% and a net margin of 12.69%. The company had revenue of $606.18 million for the quarter, compared to analyst estimates of $612.22 million. During the same quarter in the previous year, the firm posted $5.32 EPS. Chemed’s quarterly revenue was up 7.4% on a year-over-year basis. Analysts expect that Chemed Co. will post 21.43 EPS for the current year.

Chemed Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 6th. Investors of record on Monday, November 18th were paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 0.38%. The ex-dividend date was Monday, November 18th. Chemed’s dividend payout ratio is 10.11%.

Insiders Place Their Bets

In other Chemed news, VP Brian C. Judkins bought 145 shares of the stock in a transaction on Monday, December 30th. The shares were bought at an average price of $519.50 per share, with a total value of $75,327.50. Following the purchase, the vice president now directly owns 1,678 shares in the company, valued at $871,721. The trade was a 9.46 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $572.77, for a total transaction of $1,145,540.00. Following the completion of the sale, the chief executive officer now directly owns 101,735 shares of the company’s stock, valued at $58,270,755.95. This trade represents a 1.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 3.32% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on CHE shares. StockNews.com upgraded shares of Chemed from a “hold” rating to a “buy” rating in a research report on Saturday, November 30th. Royal Bank of Canada reduced their target price on shares of Chemed from $697.00 to $633.00 and set an “outperform” rating for the company in a report on Tuesday, November 5th.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.